Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,122 stopped studies mapped to Lung Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,122 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing…(NAC-PNP) | N/A | terminated | Mar 18, 2008 | Rijnstate Hospital | Unable to recruit enough patients | Enrollment / accrual |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in… | Phase 1 | terminated | Feb 27, 2017 | Novartis Pharmaceuticals | Recruitment halted prematurely due to competitive landscape for lung cancer therapies | Enrollment / accrual |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | Phase 2 | terminated | Mar 26, 2019 | Helix BioPharma Corporation | Study was halted at this time due to other budgetary priorities. Completion of reporting has been… | COVID-19 / pandemic |
| NCT02400814 | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung… | Phase 1 | terminated | Mar 27, 2015 | Megan Daly, MD | Enrollment halted due to slow accrual. | Enrollment / accrual |
| NCT04069936 | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in… | Phase 2 | terminated | Aug 28, 2019 | WindMIL Therapeutics | Resourcing | Other (stated, no rule matched) |
| NCT04560686 | Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell… | Phase 2 | terminated | Sep 23, 2020 | M.D. Anderson Cancer Center | Per PI Request | Other (stated, no rule matched) |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During…(MLAPOCHI) | Phase 2 | terminated | Dec 25, 2014 | Assistance Publique - Hôpitaux de Paris | Change in protocol strategy | Sponsor / business decision |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or… | Phase 2 | terminated | Feb 2, 2017 | Nasser Hanna, M.D. | Funder decision - lack of accrual | Enrollment / accrual |
| NCT03209128 | Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala(IPC) | — | terminated | Jul 6, 2017 | Centre Francois Baclesse, Luxembourg | diffciculties to recruit patients and a lot of patients prematurely terminated | Enrollment / accrual |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab,… | Phase 2 | terminated | Feb 10, 2017 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT03091491 | Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small… | Phase 2 | terminated | Mar 27, 2017 | National Cancer Centre, Singapore | Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of alternative… | Enrollment / accrual |
| NCT03711422 | Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | Phase 1 | terminated | Oct 18, 2018 | National Cancer Centre, Singapore | Decision to close the trial made due to low recruitment. | Enrollment / accrual |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer… | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by IRB on 3/28/22 | Other (stated, no rule matched) |
| NCT05022394 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in… | Phase 1 / Phase 2 | withdrawn | Aug 26, 2021 | M.D. Anderson Cancer Center | No participants Enrolled | Enrollment / accrual |
| NCT03904108 | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have… | Phase 2 | terminated | Apr 4, 2019 | ROGER S KERESZTES MD | insufficient patient population to complete trial as planned | Other (stated, no rule matched) |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Dec 11, 2017 | Sanofi | The study was stopped after interim analysis indicated that overall result was not sufficient to… | Efficacy / futility |
| NCT01487174 | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With… | Phase 3 | terminated | Dec 7, 2011 | Kadmon Corporation, LLC | Kadmon has made a business decision to terminate the study due to slow enrollment. Note the… | Safety / toxicity |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | Phase 4 | terminated | Aug 31, 2018 | Radboud University Medical Center | 81 patients included, difficult inclusion and full inclusion would not change the results | Other (stated, no rule matched) |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2021 | Elpiscience Biopharma, Ltd. | Sponsor's clinical development strategy adjustment | Sponsor / business decision |
| NCT02705404 | A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing | — | terminated | Mar 10, 2016 | Mayo Clinic | Additional mechanisms/trials to enroll these patients exist and competed with the trial. | Enrollment / accrual |
| NCT03054038 | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic… | Phase 1 | terminated | Feb 15, 2017 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT03754244 | A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics | Phase 1 | terminated | Nov 27, 2018 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The enrolment task cannot be gotten within the planned time.It mainly includes patients with… | Enrollment / accrual |
| NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | Phase 1 | terminated | Jun 2, 2015 | NewLink Genetics Corporation | Lack of enrollment and changing landscape of standard of care. | Enrollment / accrual |
| NCT04754815 | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced…(HFHS 21-01) | Phase 2 | withdrawn | Feb 15, 2021 | Shirish Gadgeel | Logistical challenges primarily due to COVID led to delay in starting the study and now is not felt… | COVID-19 / pandemic |
| NCT02932345 | Gefitinib Long-term Survivor Study | — | terminated | Oct 13, 2016 | AstraZeneca | Due to strategic decision, AZ has applied to terminate study at all participating sites and has… | Sponsor / business decision |
| NCT03770299 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small…(CheckMate 9TN) | Phase 2 | withdrawn | Dec 10, 2018 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02662634 | A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell… | Phase 2 | withdrawn | Jan 25, 2016 | GU Research Network, LLC | not stated | Not stated |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | Phase 2 | terminated | Jun 1, 2015 | TC Biopharm | not stated | Not stated |
| NCT04061590 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage… | Phase 2 | withdrawn | Aug 20, 2019 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1… | Phase 2 | withdrawn | Jul 14, 2020 | Shirish M Gadgeel | Lack of Accrual | Enrollment / accrual |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in… | Phase 2 | terminated | Dec 23, 2014 | Novartis Pharmaceuticals | Sponsor decision due to low patient recruitment caused by the change in the treatment landscape of… | Enrollment / accrual |
| NCT04958993 | A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With… | Phase 1 / Phase 2 | terminated | Jul 12, 2021 | Shandong Cancer Hospital and Institute | High incidence of severe radiation pneumonia | Other (stated, no rule matched) |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT04186988 | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer… | Early Phase 1 | withdrawn | Dec 5, 2019 | University of California, Davis | Unable to recruit to study. | Enrollment / accrual |
| NCT03988192 | Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy…(Immuno-VOC) | N/A | terminated | Jun 17, 2019 | Hopital Foch | Evolution of the treatment procedures so that their is no more benefits for patients | Other (stated, no rule matched) |
| NCT03255083 | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor… | Phase 1 | terminated | Aug 21, 2017 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT04758949 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Feb 17, 2021 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT03319316 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non…(SOLUTION) | Phase 2 | withdrawn | Oct 24, 2017 | European Organisation for Research and Treatment of Cancer - EORTC | Interest withdrawn | Other (stated, no rule matched) |
| NCT02963610 | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With… | Phase 1 / Phase 2 | terminated | Nov 15, 2016 | Fox Chase Cancer Center | Study terminated prematurely due to funding/support being withdrawn by grantor | Funding |
| NCT00372073 | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | Phase 2 | terminated | Sep 6, 2006 | Cyclacel Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00885963 | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung… | Phase 2 | terminated | Apr 22, 2009 | Cyclacel Pharmaceuticals, Inc. | Limitation in financial resources. | Funding |
| NCT03990077 | Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | Phase 1 | terminated | Jun 18, 2019 | Shanghai Kechow Pharma, Inc. | drug development strategy adjustment | Sponsor / business decision |
| NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or… | Phase 2 | terminated | Aug 17, 2009 | SCRI Development Innovations, LLC | Study was terminated due to slow accrual | Enrollment / accrual |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | Phase 1 / Phase 2 | terminated | Nov 15, 2019 | Eli Lilly and Company | The study was terminated due to an unexpected toxicity finding. | Safety / toxicity |
| NCT03231475 | Phase I Study of SPH1188-11 in NSCLC(SPH1188-11) | Phase 1 | withdrawn | Jul 27, 2017 | Shanghai Pharmaceuticals Holding Co., Ltd | Board decision | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 31, 2022source: clinicaltrials